CAS Number: 149709-62-6

Stage: Pipeline

Sacubitril, in combination with valsartan, forms a neprilysin inhibitor/ARB combination marketed for heart failure with reduced ejection fraction (HFrEF). Sacubitril enhances natriuretic peptides, promoting vasodilation and natriuresis, thereby improving heart function. This dual-action therapy has redefined the standard of care in chronic heart failure. Explore Royal Pharma as your potential partner for Sacubitril API.